In Science this week: researchers engineer tobacco plant to produce chemotherapy precursor, predicting patient response to immunotherapy difficult, and more.
The researchers combined CRISPR knockouts with RNAi screening to overcome key limitations in using the gene-silencing technology to identify new drug targets.
The company was established by a co-founder of Beeologics, which was developing RNAi treatments for bee diseases before its acquisition by Monsanto.
In PLOS this week: gauging species divergence time, differentially expressed genes in female mosquitos during reproduction, and more.
Researchers used RNA interference and automated trait analyses to systematically track phenotypes in Caenorhabditis elegans worms from two genetic backgrounds.
In the study, the scientists used RNAi screening, whole-exome sequencing, and affinity proteomics to identify genes involved in cilia formation, as well as disease-causing defects.
Seth Bordenstein of Vanderbilt University will use the award to find genes that respond to inherited bacterial infections in insects.
The findings further point to the importance of the stability and dosage of RNAi molecules to gene silencing in environmental RNAi-sensitive insects.
The study is being conducted in Sierra Leone by the University of Oxford.
The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.